knowledge -WSS

knowledge

author：fashion 2025-09-28 10:52:47 - browse：944

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： US soldier in North Korean custody after crossing DMZ line

focus

WSS

Federal weight loss drug coverage is 30 years out of date

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Lack of darker skin in textbooks, journals harms patients of color

The biotech scorecard for Q1: 17 stock

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

focus

knowledge

focus

How to save PrEP access — and even expand it

Federal weight loss drug coverage is 30 years out of date

Sports medicine is finally prioritizing gender equality

Antibiotic resistance and the global rise in human conflict

Medical records are filled with copy

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Duchenne breakthrough therapy leaves behind pioneering families

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Cancer drug shortages should be causing more outrage

Morgan Health, with ambitious aims, wants you to know it’s still here

hotspot

Goldman Sachs launches $650M fund for life science investments

A single drug, study failures leave Anavex with nothing but cash

Feng Zhang CRISPR delivery startup lays off quarter of staff

The biotech scorecard for Q1: 17 stock

Study: Hearing aids may slow cognitive decline in those at risk

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

hotspot

leisure time

focus

focus